Compare Mesoblast Limited (MESO) vs Banco Santander SA (SAN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Mesoblast Limited vs Banco Santander SA — how do they compare? Mesoblast Limited trades at $16.36 (market cap $2.17B), while Banco Santander SA trades at $13.68 (market cap $191.46B). The key difference: Banco Santander SA is far larger — about 88.2× Mesoblast Limited's market cap, and Banco Santander SA pays a 2.09% dividend while Mesoblast Limited pays none. Which is the better fit depends on your goals.
| MESO | SAN | |
|---|---|---|
Market Cap | $2.17B | $191.46B |
Sector | Technology | Financials |
52-Week High | $20.96 | $14.37 |
52-Week Low | $12.88 | $8.40 |
Enterprise Value | $2.17B | — |
Dividend Yield | — | 2.09% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
MESO trades at $16.63, down 3.98% on the day, with a bullish technical outlook supported by moving averages. The company shows strong revenue growth with Ryoncil generating $115 million in annual revenue, though it remains unprofitable with a net loss of $102 million. Recent developments include positive Phase 3 trial progress and FDA BLA filings for new treatments.
Investment outlook balances promising pipeline progress against significant financial losses. The stock offers growth potential through commercial expansion but carries substantial risk from continued cash burn and regulatory hurdles. Analyst consensus leans bullish with 45% buy ratings, reflecting optimism about the company's transition to commercial-stage operations.
Banco Santander (SAN) trades at $13.31, down 1.77% on the day, with a neutral technical signal and mixed earnings history. The company reported Q1 2026 EPS of $0.41, beating expectations, but missed in prior quarters. Revenue for 2025 was $60.02B with a net income margin of 26.72%. Recent news highlights Santander's AI initiatives, acquisition of Webster Bank, and becoming Spain's most valuable company. Cash flow trends show operational challenges, with net cash flow negative in recent years.
Outlook is cautiously optimistic with a 64% analyst buy rating, targeting efficiency gains and AI-driven value. Risks include regulatory probes, declining cash flows, and high debt levels. The stock offers a dividend yield with the recent $0.15 payout, but investors should weigh operational improvements against financial volatility and macroeconomic pressures in the banking sector.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Mesoblast Limited
Mesoblast Limited is a global leader in allogeneic cellular medicines. The company develops innovative, commercially-ready mesenchymal lineage cell (MLC) technology for the treatment of various inflammatory and cardiovascular conditions. Their pipeline focuses on leveraging the anti-inflammatory, tissue repair, and immune-modulating properties of these cells for diseases with high unmet medical needs, such as acute graft versus host disease (aGVHD) and chronic heart failure.
Read more on MESO →About Banco Santander SA
Santander's focus is on retail and commercial banking. Latin America is geographically the largest operation, with Brazil by far the largest. Its continental European business is still mainly Iberian. Santander's U.K. presence is the result of the acquisition of building society Abbey. In the U.S., Santander operates a vehicle finance business and a regional bank focused on the Northeastern states.
Read more on SAN →
